Retatrutide vs Tirzepatide vs Semaglutide for Weight Loss: What’s the Difference?
Medical weight loss is moving quickly. Semaglutide and tirzepatide are already familiar to many patients, while retatrutide has generated interest because clinical trials are studying a three-receptor approach to obesity treatment.
These medications should not be compared by simply placing the largest weight-loss percentage from each trial side by side. They target different receptors, have different regulatory status, and have been studied in different populations and trial designs.
This article explains what separates semaglutide, tirzepatide, and retatrutide, what the retatrutide clinical trials have reported so far, and what patients should understand before interpreting the numbers.
Retatrutide vs Tirzepatide vs Semaglutide for Weight Loss: What’s the Difference?
Three approaches to metabolic weight management, with different receptor targets and different levels of clinical and regulatory evidence.
Written by Dr. Alexander Shapsis, MD, FACS
Board-Certified Gastroenterologist • EndoSlim Clinic NY
Quick Answer
Semaglutide targets GLP-1 receptors. Tirzepatide targets GIP and GLP-1 receptors. Retatrutide targets GIP, GLP-1, and glucagon receptors, earning the description “triple agonist.” Retatrutide has produced substantial weight loss in clinical trials, but it remains investigational and is not an FDA-approved medication.
Retatrutide vs Tirzepatide vs Semaglutide
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor targets | GLP-1 | GIP + GLP-1 | GIP + GLP-1 + glucagon |
| Often described as | Single agonist | Dual agonist | Triple agonist |
| Weight-management brand | Wegovy® | Zepbound® | No approved brand |
| Current status | FDA-approved for labeled indications | FDA-approved for labeled indications | Investigational |
Why Is Retatrutide Called a “Triple G” Agonist?
Retatrutide activates receptors for GIP, GLP-1, and glucagon. Researchers are studying whether combining these pathways can affect appetite, food intake, metabolic regulation, and energy balance.
For the deeper science, read How Does Retatrutide Make You Lose Weight? The Science of the “Triple G” Agonist.
How Is Retatrutide Different From Semaglutide?
Semaglutide is a GLP-1 receptor agonist. Retatrutide also activates GLP-1 receptors but adds GIP and glucagon receptor activity.
Patients interested in currently available therapy can learn about Ozempic® & Wegovy® / semaglutide treatment.
How Is Retatrutide Different From Tirzepatide?
Tirzepatide activates GIP and GLP-1 receptors. Retatrutide adds glucagon receptor activity. The additional target is scientifically important, but receptor count alone does not establish clinical superiority.
Explore Mounjaro® & Zepbound® / tirzepatide treatment or our Ozempic® vs Zepbound® comparison.
How Much Weight Did Participants Lose With Retatrutide?
In the published Phase 2 obesity trial, the 12-mg retatrutide group had a mean weight change of −24.2% at 48 weeks, compared with −2.1% for placebo.
More recently, Lilly reported topline Phase 3 TRIUMPH-1 results: participants assigned to 12 mg lost an average 28.3% at 80 weeks, and 45.3% achieved at least 30% weight loss. These Phase 3 figures are company-reported topline results and should be interpreted as such until the full peer-reviewed dataset is available.
Does This Mean Retatrutide Works Better?
Not from separate trials alone. A retatrutide trial cannot simply be placed next to a semaglutide or tirzepatide trial and treated as a randomized head-to-head comparison. Populations, durations, doses, adherence, estimands, and study methods can differ.
What Side Effects Have Retatrutide Trials Reported?
In the published Phase 2 trial, the most common adverse events were gastrointestinal and were generally dose-related. Researchers reported that a lower starting dose partly reduced these effects. Dose-dependent increases in heart rate were also observed, peaking around week 24 and declining afterward.
Safety evaluation remains particularly important because retatrutide is still an investigational medication.
Can You Get Retatrutide for Weight Loss Right Now?
Retatrutide is not currently an FDA-approved medication. The FDA states that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law.
Patients should be cautious of websites, telehealth companies, or sellers advertising “compounded retatrutide” or research products for personal weight-loss use.
What Can Patients Discuss With a Doctor Now?
Patients seeking medical weight management do not need to wait for investigational drugs to discuss evidence-based options. Depending on medical history and eligibility, currently available treatments may include semaglutide, tirzepatide, or procedure-based options such as Endoscopic Sleeve Gastroplasty (ESG).
Continue Exploring Medical Weight Loss
Questions About Your Current Weight-Loss Options?
At EndoSlim Clinic NY in Brooklyn, Dr. Alexander Shapsis can review your medical history, BMI, previous treatment, goals, and currently available medical or endoscopic options.
Serving: Brooklyn, Manhattan, Queens, the Bronx, Staten Island, Long Island, New Jersey, and Connecticut.
Additional educational resource: Patients interested in learning more about retatrutide research and ongoing developments may review additional educational information here.
-
Mon-Friday: 08:30 - 6:00Saturday: ClosedSaturday: Closed